diethyl 1-(2-cyanoethyl)-1H-indole-2,6-dicarboxylate | 1311368-88-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: diethyl 1-(2-cyanoethyl)-1H-indole-2,6-dicarboxylate
• 英文别名: diethyl 1-(2-cyanoethyl)indole-2,6-dicarboxylate
• CAS: 1311368-88-3
• 化学式: C₁₇H₁₈N₂O₄
• 分子量: 314.341
• InChiKey: VIXDBKPFQBKCRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  81.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  diethyl 1-(2-cyanoethyl)-1H-indole-2,6-dicarboxylate 在 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  Synthesis and SAR studies of indole-based MK2 inhibitors

  摘要：

  Chemistry has been developed to specifically functionalize two structurally similar classes of indole-based MK2 inhibitors at positions prompted by a combination of X-ray crystallographic and computer assisted drug design. A gain in molecular potency was obtained by introducing aminomethyl groups to the lactam rings of 6-arylcarbamoyl-tetrahydro-beta-carbolinone and 6-arylcarbamoyl-dihydropyrazino[1,2-a] indolone MK2 inhibitors. In addition, improvements in molecular potency were achieved by expansion of the lactam from a 6- to 7-membered ring leading to 7-arylcarbamoyl-tetrahydro-[1,4] diazepino[1,2-a]indolones. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.119
• 作为产物：
  描述：

  4-甲基-3-硝基苯甲酸 在 盐酸 、 sodium ethanolate 、 溶剂黄146 、 锌 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醇 、 水 为溶剂， 反应 55.5h， 生成 diethyl 1-(2-cyanoethyl)-1H-indole-2,6-dicarboxylate
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE
  [FR] COMPOSÉS HÉTÉROCYCLIQUES CONTENANT UN COEUR INDOLE

  摘要：

  公开了抑制RSK的新颖化合物，制造此类化合物的方法以及包含此类化合物的药物组合物。还公开了使用本发明的化合物治疗RSK2调控失调的方法。

  公开号：

  WO2011071716A1

文献信息

• HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE
  申请人：Boyer Stephen James

  公开号：US20130109679A1

  公开（公告）日：2013-05-02

  Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.

  本发明揭示了一种新型化合物，可抑制RSK，制备这种化合物的方法以及包含这种化合物的药物组合物。本发明还揭示了使用本发明化合物治疗RSK2调节的疾病的方法。
• Heterocyclic compounds containing an indole core
  申请人：Boyer Stephen J.

  公开号：US09150577B2

  公开（公告）日：2015-10-06

  Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.

  本发明涉及一种新型化合物，其可以抑制RSK，并且涉及制备这种化合物的方法以及包含这种化合物的制药组合物。本发明还涉及使用本发明的化合物治疗RSK2调节的疾病的方法。
• US9150577B2
  申请人：——

  公开号：US9150577B2

  公开（公告）日：2015-10-06
• [EN] HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONTENANT UN COEUR INDOLE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2011071716A1

  公开（公告）日：2011-06-16

  Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.

  公开了抑制RSK的新颖化合物，制造此类化合物的方法以及包含此类化合物的药物组合物。还公开了使用本发明的化合物治疗RSK2调控失调的方法。
• Synthesis and SAR studies of indole-based MK2 inhibitors
  作者：Zhaoming Xiong、Donghong Amy Gao、Derek A. Cogan、Daniel R. Goldberg、Ming-Hong Hao、Neil Moss、Edward Pack、Chris Pargellis、Donna Skow、Thomas Trieselmann、Brian Werneburg、Andre White

  DOI：10.1016/j.bmcl.2008.01.119

  日期：2008.3

  Chemistry has been developed to specifically functionalize two structurally similar classes of indole-based MK2 inhibitors at positions prompted by a combination of X-ray crystallographic and computer assisted drug design. A gain in molecular potency was obtained by introducing aminomethyl groups to the lactam rings of 6-arylcarbamoyl-tetrahydro-beta-carbolinone and 6-arylcarbamoyl-dihydropyrazino[1,2-a] indolone MK2 inhibitors. In addition, improvements in molecular potency were achieved by expansion of the lactam from a 6- to 7-membered ring leading to 7-arylcarbamoyl-tetrahydro-[1,4] diazepino[1,2-a]indolones. (C) 2008 Elsevier Ltd. All rights reserved.